Danaher’s management indicated that fourth quarter 2025 revenues are projected to rise in the mid-single-digit percentage range compared with the same period in 2024. Core non-GAAP revenue growth is expected toward the high end of the company’s previously announced low-single-digit guidance, reflecting incremental strength in its key end markets and favorable contribution from recent bolt-on acquisitions.

Rainer M. Blair highlighted that Bioprocessing delivered continued robust growth, driven by increased demand for single-use technologies and chromatography resins. Life Sciences products outperformed expectations thanks to strong instrument placements in genomics and proteomics, while Diagnostics revenue benefited from higher volume in immunoassay platforms and molecular testing consumables. Each of these three segments contributed approximately one-third of the quarter’s core growth, underpinned by price realization and new product introductions.

For the full year, Danaher expects non-GAAP adjusted diluted net earnings per share to reach the high end of its previously announced range of $7.70 to $7.80. This projection assumes continued operational leverage, disciplined cost management and ongoing contributions from recent acquisitions. The company’s effective tax rate is forecast in a mid-20% range, and capital expenditure spending is planned at approximately 4% of sales for 2025.

Blair emphasized the role of the Danaher Business System in sustaining productivity gains and supporting innovation pipelines across the portfolio. The company plans to deploy free cash flow toward strategic M&A, share repurchases and debt reduction. With approximately 63,000 associates worldwide and a strong balance sheet, Danaher reiterated its commitment to fund R&D at 8–9% of revenues and return at least 50% of free cash flow to shareholders over the next three years.